



# Dr. K. Kiran Kumar

Qualification: MD, DNB (Radiation Therapy)

**Department:** Radiation Oncology

**Designation:** Sr. Consultant Radiation Oncologist

Languages: English, Hindi, Telugu

**Experience:** 18 yrs

#### **About the Doctor**

Dr. K. Kiran Kumar is a Consultant Radiation Oncologist at Yashoda Hospitals, Somajiguda, with over 18 years of experience.

#### **Educational Qualifications**

■ MD, DNB (Radiation Therapy)

### **Experience**

- 2008-Present: Consultant Radiation Oncologist, Yashoda Hospitals, Somajiguda
- 2007-2008: Registrar, Department of Radiation Oncology

### **Services Offered**

- Brachytherapy (Internal Radiation Therapy)
- External Beam Radiation for Prostate Cancer
- Radiation Oncology
- Advanced Techniques (SBRT, IMRT, IGRT)

Cancer Screening (Preventive)

- SBRT/SABR (Stereotactic Body Radiotherapy) for Cancerous Tumours
- Stereotactic Radiosurgery (SRS) for Brain & Spine Tumours
- External Beam Radiotherapy (EBRT)
- Image Guided Radiotherapy (IGRT)
- Teleradiotherapy
- Accelerated Partial Breast Radiotherapy
- Hormone Therapy for Breast Cancer
- Hormone Therapy for Prostate Cancer
- Pap Smear

## **Professional Membership**

- ARIO
- IMA
- ESMO

### **Research & Publications**

- Principal Investigator in Trial no 1200.161, Trial title-A randomized, open-label, phase III study to evaluate the efficacy and safety of oral afatinib versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who have progressed after platinum-based therapy
- Principal Investigator trial number: 1200:131 Trial title-LUX-Head and Neck 2: randomised, double blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa, or IVb loco-regionally advanced head and neck squamous cell carcinoma
- Title: P276-00/64/11 ?A Multicenter, Phase II/III study to assess radiation induced mucositis in subjects with locally advanced squamous cell carcinoma of the head and neck, administered cisplatin and radiation with or without P276-00
- Title NETU08-18: A phase III multicenter, randomized, double-blind, double-dummy, active-controlled, parallel group study of the efficacy and safety of oral netupitant administered in combination with palonosetron and dexamethasone compared to oral palonosetron and dexamethasone for the prevention of nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy
- Title: PALO10-01: Single dose, multicenter, randomized, double-blind, double-dummy, parallel group study to assess the efficacy and safety of oral palonosetron 0.50 mg compared to I.V palonosetron 0.25mg administered with dexamthasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic cisplatin-based chemotherapy